Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01420627 · ClinicalTrials.gov registry record · Phase 3
EZN-2279 in Patients With ADA-SCID
A Phase 3 study, sponsored by Leadiant Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT01420627: Completed Phase 3 study, sponsored by Leadiant Biosciences.
NCT01420627 is a Phase 3 study that has completed, run by Leadiant Biosciences. The registered enrollment target is 7 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01420627, a Phase 3 study, has completed, sponsored by Leadiant Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.
Primary Outcome
Number of patients with total erythrocyte dAXP concentration from a trough blood sample \<0.02 mmol/L
Interventions
- BIOLOGICAL EZN-2279
- BIOLOGICAL Adagen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-01-24 |
| Est. Completion | 2019-05-29 |
| Phase | Phase 3 |
What the finished NCT01420627 record still lists
NCT01420627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which EZN-2279 is the first listed.
NCT01420627 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01420627 about?
NCT01420627 is a clinical study titled "EZN-2279 in Patients With ADA-SCID". The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.
What is the current status of trial NCT01420627?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2014-01-24. Estimated completion is 2019-05-29.
What interventions are being tested in trial NCT01420627?
The interventions under investigation include: EZN-2279 (BIOLOGICAL), Adagen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01420627?
This trial is sponsored by Leadiant Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01420627's enrollment target sits among peer trials
7 1995th of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI